Literature DB >> 16133664

Retrospective analysis of predictive factors for recurrence after curatively resected papillary thyroid carcinoma.

Katsuhiro Tanaka1, Hiroshi Sonoo, Mai Hirono, Sumiko Ohkubo, Tsunehisa Nomura, Masahiko Ikeda, Kazukata Nakajima, Junichi Kurebayashi.   

Abstract

PURPOSE: This retrospective study analyzes the predictive factors after curative surgery for papillary thyroid carcinoma (PTC).
METHODS: We analyzed 386 patients who underwent a curative operation for PTC in our hospital between 1977 and 1997, subject to the inclusion criteria.
RESULTS: According to univariate analysis, pathological lateral cervical lymph node involvement (P < 0.0001), dedifferentiation of the tumor (P < 0.002), male sex (P < 0.0001), a large tumor (P < 0.005), and an age of over 50 years (P < 0.05) were significant factors. Cox's proportional hazard model showed that a man (P < 0.05), aged over 50 years (P < 0.05), who had a large primary tumor (P < 0.05) with dedifferentiation (P < 0.05), and pathological lateral cervical lymph node metastasis (P < 0.005) was more likely to have recurrence of PTC.
CONCLUSIONS: Determining whether lymph node metastasis exists could be useful for predicting recurrence in patients who have undergone curative resection of PTC.

Entities:  

Mesh:

Year:  2005        PMID: 16133664     DOI: 10.1007/s00595-005-3021-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  29 in total

Review 1.  Role of thyroid stimulating hormone suppression in the management of thyroid cancer.

Authors:  C G Thomas
Journal:  Semin Surg Oncol       Date:  1991 Mar-Apr

Review 2.  Prognostic variables of papillary and follicular thyroid carcinoma patients with lymph node metastases and without distant metastases.

Authors:  J D Lin; M J Liou; T C Chao; H F Weng; Y S Ho
Journal:  Endocr Relat Cancer       Date:  1999-03       Impact factor: 5.678

3.  Localization of cervical node metastasis of papillary thyroid carcinoma.

Authors:  E Mirallié; J Visset; C Sagan; A Hamy; M F Le Bodic; J Paineau
Journal:  World J Surg       Date:  1999-09       Impact factor: 3.352

4.  Neck dissection for surgical treatment of lymphnode metastasis in papillary thyroid carcinoma.

Authors:  M Ducci; M Appetecchia; M Marzetti
Journal:  J Exp Clin Cancer Res       Date:  1997-09

5.  The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

Authors:  R W Tsang; J D Brierley; W J Simpson; T Panzarella; M K Gospodarowicz; S B Sutcliffe
Journal:  Cancer       Date:  1998-01-15       Impact factor: 6.860

6.  Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

Authors:  F D Gilliland; W C Hunt; D M Morris; C R Key
Journal:  Cancer       Date:  1997-02-01       Impact factor: 6.860

7.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

8.  Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer.

Authors:  M C Coburn; H J Wanebo
Journal:  Am J Surg       Date:  1992-12       Impact factor: 2.565

9.  Significance of lymph node metastasis in differentiated thyroid cancer.

Authors:  J Harwood; O H Clark; J E Dunphy
Journal:  Am J Surg       Date:  1978-07       Impact factor: 2.565

10.  Metastases to the regional lymph nodes, lymph node recurrence, and distant metastases in nonadvanced papillary thyroid carcinoma.

Authors:  K Sugino; Y Kure; H Iwasaki; O Ozaki; T Mimura; A Matsumoto; K Ito
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

View more
  8 in total

1.  Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis.

Authors:  Y Liu; X Yun; M Gao; Y Yu; X Li
Journal:  Clin Transl Oncol       Date:  2014-11-12       Impact factor: 3.405

Review 2.  Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis.

Authors:  Kai Guo; Zhuoying Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.

Authors:  Su-jin Kim; Kyu Eun Lee; Jun Pyo Myong; Jeong-hwan Park; Yoon Kyung Jeon; Hye Sook Min; So Yeon Park; Kyeong Cheon Jung; Do Hoon Koo; Yeo-Kyu Youn
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

4.  EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines.

Authors:  Yongsheng Jia; Cuicui Zhang; Chuanxiang Hu; Yang Yu; Xiangqian Zheng; Yigong Li; Ming Gao
Journal:  Oncol Lett       Date:  2018-02-21       Impact factor: 2.967

5.  Analysis of Risk Factors Contributing to Recurrence of Papillary Thyroid Carcinoma in Chinese Patients Who Underwent Total Thyroidectomy.

Authors:  Wei Zhang; De Jiao; Baoguo Liu; Shanping Sun
Journal:  Med Sci Monit       Date:  2016-04-16

6.  Neglected papillary thyroid carcinoma seven years after initial diagnosis.

Authors:  Eleftherios D Spartalis; Theodore Karatzas; Petros Charalampoudis; Chrysovalantis Vergadis; Dimitrios Dimitroulis
Journal:  Case Rep Oncol Med       Date:  2013-01-14

7.  Utility of Thyroglobulin measurement in fine-needle aspiration biopsy specimens of lymph nodes in the diagnosis of recurrent thyroid carcinoma.

Authors:  Zubair W Baloch; Julieta E Barroeta; Janet Walsh; Prabodh K Gupta; Virginia A Livolsi; Jill E Langer; Susan J Mandel
Journal:  Cytojournal       Date:  2008-01-31       Impact factor: 2.091

8.  Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.

Authors:  Seokho Yoon; Young-Sil An; Su Jin Lee; Eu Young So; Jang-Hee Kim; Yoon-Sok Chung; Joon-Kee Yoon
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.